In order to target tumor cell mitochondria, applying biguanides to replacement therapy or drug repositioning should be proposed for patients with SOD2-abundant RCC for maintenance phase treatments after primary surgery debulking numbers of RCC cells. Here, SOD2 is linked to neoplasm.